Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients

British Journal of Haematology

Volumn 121, Issue 1, 2003, Pages 187-189

  Mourad, Fadi H ^a   Hoffbrand, A Victor ^b,e   Sheikh Taha, Marwan ^c   Koussa, Susane ^d   Khoriaty, Adlette I ^d   Taher, Ali ^a,d  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c LEBANESE AMERICAN UNIVERSITY   (Lebanon)

^d Chronic Care Center Hazmieh   (Lebanon)

^e ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Deferiprone; Desferrioxamine; Iron chelation; Thalassaemia

Indexed keywords

DEFERIPRONE; DEFEROXAMINE; FERRITIN; NONSTEROID ANTIINFLAMMATORY AGENT;

ABDOMINAL DISCOMFORT; ADULT; ANOREXIA; ARTHRALGIA; ARTICLE; BLOOD TRANSFUSION; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EDEMA; ERYTHEMA; FATIGUE; FEMALE; FERRITIN BLOOD LEVEL; HEADACHE; HUMAN; INJECTION SITE; IRON CHELATION; IRON INTAKE; IRON OVERLOAD; IRON URINE LEVEL; JOINT STIFFNESS; MALE; NAUSEA; PAIN; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SKIN INDURATION; SKIN MANIFESTATION; THALASSEMIA MAJOR; URINARY EXCRETION;

ADOLESCENT; ADULT; BETA-THALASSEMIA; BLOOD TRANSFUSION; CHELATING AGENTS; CHILD; DEFEROXAMINE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FERRITINS; HUMANS; IRON; IRON OVERLOAD; MALE; PYRIDONES; STATISTICS, NONPARAMETRIC;

EID: 0242584372     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2003.04240.x     Document Type: Article

References (7)

1. Balveer, K., Pyar, K. & Wonke, B. (2000) Combined oral and parenteral iron chelation in beta thalassaemia major. Medical Journal of Malaysia, 55, 493-497.
2. Barman Balfour, J.A. & Foster, R.N. (1999) Deferiprone. A review of its clinical potential in iron overload in β-thalassaemia major and other transfusion dependent diseases. Drugs, 58, 553-578.
3. Breuer, W., Ermers, M.J., Pootrakul, P., Abramov, A., Hershko, C. & Cabantchik, Z.I. (2001) Desferrioxamine-chelatable iron, a component of serum non-transferrin-bound iron, used for assessing chelation therapy. Blood, 97, 792-798.
4. Hoffbrand, A., Al-Refaie, F., Davis, B., Siritanakatkul, N., Jackson, B., Cochrane, J., Prescott, E. & Wonke, B. (1998) Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients. Blood, 91, 295-300.
5. Olivieri, N.F., Brittenham, G.M., McLaren, C.E., Templeton, D.M., Cameron, R.G., McClelland, R.A., Burt, A.D. & Fleming, K.A. (1998) Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassaemia major. New England Journal of Medicine, 339, 417-423.
6. Taher, A., Sheikh-Taha, M., Koussa, S., Inati, I., Neeman, R. & Mourad, F.H. (2001) Comparison between desferrioxamine and deferiprone (L1) in iron-loaded thalassaemia patients. European Journal of Haematology, 67, 30-34.
7. Wonke, B., Wright, C. & Hoffbrand, A.V. (1998) Combined therapy with deferiprone and desferrioxamine. British Journal of Haematology, 103, 361-364.